Quantitative Investment Management LLC Sells 8,444 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Quantitative Investment Management LLC cut its IQVIA stake by 47.6%, selling 8,444 shares and retaining 9,301 shares valued at approximately $1.8 million. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations with $3.15 in EPS and $4.37 billion in revenue, representing 8.7% year-over-year growth. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $241.88 target price, while IQVIA’s board authorized a $2 billion share-repurchase program covering up to 6.8% of outstanding shares.

Quantitative Investment Management LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 47.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 9,301 shares of the medical research company's stock after selling 8,444 shares during the quarter. Quantitative Investment Management LLC's holdings in IQVIA were worth $1,797,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth $27,000. Compass Financial Management LLC acquired a new position in IQVIA in the 2nd quarter valued at $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA in the 4th quarter worth $27,000. CrossGen Wealth LLC acquired a new position in IQVIA during the 4th quarter worth $28,000. Finally, Financial Freedom LLC acquired a new stake in shares of IQVIA in the first quarter valued at about $25,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company's stock, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on IQV. Robert W. Baird boosted their price objective on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Stifel Nicolaus upped their price target on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Finally, Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Stock Performance

IQV opened at $261.29 on Tuesday. The stock's 50 day simple moving average is $224.00 and its 200-day simple moving average is $190.15. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $43.01 billion, a PE ratio of 32.42, a P/E/G ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $265.25.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same period last year, the business earned $2.81 earnings per share. IQVIA's quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.